CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Regulatory T cells (Tregs) are often enriched in tumors, where their immunosuppressive function has a key role in tumor persistence and progression. In colorectal cancer (CRC), however, Tregs are frequently associated with an improved clinical outcome. Tumor-infiltrating Tregs have been shown to exhibit a distinct signature comprising the co-stimulatory molecules (OX40, 4-1BB), cytokine receptors (IL1R2, IL21R, CCR8, CD30), and co-inhibitory molecules (PD-L1, TIGIT). Here, we showed by flow cytometry that circulating CD45RO+Tregs from patients with CRC (n = 25) have elevated CD30 and OX40 expression compared to healthy subjects (n = 14). We identified co-expression of CD30 and OX40 on circulating CD45RO+Tregs using single-cell images captured by the DEPArray™system. The frequency of CD30+OX40+CD45RO+Tregs was significantly higher in CRC patients than in healthy subjects (P < 0.001). Importantly, receiver operating characteristic analysis confirmed that this CD30+OX40+Treg subset could strongly discriminate between CRC patients and healthy subjects with the highest accuracy of 92.3%, an AUC of 0.92, a sensitivity of 88%, a specificity of 100%, a positive predictive value of 100%, a negative predictive value of 82.35%, and a trade-off value of 3.44%, compared to other Treg subsets. Consistently, multiplex-IHC/IF of tumor-infiltrating Tregs revealed a significant association between high densities of CD30+OX40+Tregs and improved overall survival; no such association was found for other subsets. These data suggest a potential role for CD30+OX40+Tregs as a diagnostic or prognostic biomarker in CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tregs suppress the harmful inflammatory response and thus exhibit positive benefits in patients with several types of cancers, including colorectal cancer (CRC) and head and neck tumors (HNC) [16, 18–21].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tregs suppress microbial-induced inflammation, therefore decreasing susceptibility to tumors [16].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies on various types of malignant tumors, such as CRC, HNSCC, and gastric cancer (GC), have shown a positive correlation between Tregs infiltration and prolonged survival of cancer patients [16, 18, 20, 34, 35].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
FOXP3+ regulatory T cells in the human immune system
Sakaguchi, S., Miyara, M., Costantino, C. M., & Hafler, D. A. (2010) · Nature Reviews Immunology · doi:10.1038/nri2785 · Cited by 2,439
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
Zhang, L., Yu, X., Zheng, L., Zhang, Y., Li, Y., Fang, Q., Gao, R., Kang, B., Zhang, Q., Huang, J. Y., et al. (2018) · Nature · doi:10.1038/s41586-018-0694-x · Cited by 1,505
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., & Banham, A. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9584 · Cited by 1,200
Research works printed but not linked: 1
- Garnelo M Tan A Her Z Yeong J Lim CJ Chen J Lim KH Weber A Chow P Chung A Ooi LL Toh HC Heikenwalder M Ng IO Nardin A Chen Q Abastado JP Chew V Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma Gut 2017 66 2 342 351 10.1136/gutjnl-2015-310814 26669617 PMC5284473 · DOI · Paper page
Cited by
Therapeutic targeting of regulatory T cells in cancer
Shan, F., Somasundaram, A., Bruno, T. C., Workman, C. J., & Vignali, D. A. A. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.06.008 · Cited by 244
CD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 185
Regulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 158
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
Wang, Y., Li, J., Nakahata, S., & Iha, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137346 · Cited by 97
Supino, D., Minute, L., Mariancini, A., Riva, F., Magrini, E. I., & Garlanda, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804641 · Cited by 77
Integrated BATF transcriptional network regulates suppressive intratumoral regulatory T cells
Shan, F., Cillo, A. R., Cardello, C., Yuan, D. Y., Kunning, S. R., Cui, J., Lampenfeld, C., Williams, A. M., McDonough, A. P., Pennathur, A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.adf6717 · Cited by 38
Jiang, Z., Zhu, H., Wang, P., Que, W., Zhong, L., Li, X., & Du, F. (2022) · MedComm · doi:10.1002/mco2.137 · Cited by 38
Abdeladhim, M., Karnell, J. L., & Rieder, S. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1033705 · Cited by 40
Biomarkers and experimental models for cancer immunology investigation
Xu, H., Jia, Z., Liu, F., Li, J., Huang, Y., Jiang, Y., Pu, P., Shang, T., Tang, P., Zhou, Y., et al. (2023) · MedComm · doi:10.1002/mco2.437 · Cited by 24
Chen, Z., Li, Q., Lin, Y., Lin, S., Gao, J., & Chen, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-37300-z · Cited by 21
Many Faces of Regulatory T Cells: Heterogeneity or Plasticity?
Blinova, V. G., & Zhdanov, D. D. (2024) · Cells · doi:10.3390/cells13110959 · Cited by 20
Stayoussef, M., Xu, W., Habel, A., Barbirou, M., Bedoui, S., Attia, A., Omrani, Y., Zouari, K., Maghrebi, H., Almawi, W. Y., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03746-x · Cited by 16
Chang-qin, L., & Li, J. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104543 · Cited by 14
Regulatory T cells in liver metastases: emerging and divergent roles in tumour progression
Wu, G., Yang, T., Gholami, S., DePeralta, D. K., Weiss, M. J., Deng, M., Wang, P., & Huang, H. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100257 · Cited by 14
Koukourakis, I. M., Platoni, K., TINIAKOS, D. G., Kouloulias, V., & Zygogianni, A. G. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050285 · Cited by 13
Khalil, R. G., Mohammed, D. A., Hamdalla, H. M., & Ahmed, O. M. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156834 · Cited by 11
Ridnour, L. A., Cheng, R. Y. S., Heinz, W. F., Pore, M. M., González, A. L., Femino, E. L., Moffat, R. L., Wink, A. L., Imtiaz, F., Coutinho, L. L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.193091 · Cited by 9
Wang, T., Tang, L., Ouyang, B., Chen, X., & Qi, J. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1169 · Cited by 7
Beyond Negative Regulation: IL‐1R8 and IL‐1R2 as Novel Immune Checkpoints
Supino, D., Garuti, R., & Garlanda, C. (2025) · European Journal of Immunology · doi:10.1002/eji.70050 · Cited by 6
Gao, Z., Zhang, Q., Zhang, X., & Song, Y. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221092900 · Cited by 7
Dzhalilova, D. S., Silina, M. V., Kosyreva, A. M., Fokichev, N., & Makarova, O. V. (2025) · PeerJ · doi:10.7717/peerj.19024 · Cited by 7
Exploring BIRC family genes as prognostic biomarkers and therapeutic targets in prostate cancer
Yu, X., Liu, Y., Mo, Z.-M., Luo, R.-J., & Chen, W.-K. (2025) · Discover Oncology · doi:10.1007/s12672-025-02002-7 · Cited by 6
Chen, Z., Lin, Y., 林素勇, Yang, X., & Chen, S. (2022) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i11.1951 · Cited by 3
Murphy, C., Devis, L., Struck, R., Boloix, A., Gallagher, C., Gavin, C., Cottone, F., Soriano, A., Madden, S. F., Roma, J. M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0303643 · Cited by 3
Luo, Y., Li, J., Li, L. Y., Qin, B., Zhou, R., & Tang, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1724756 · Cited by 3
The insider's perspective: The intracellular complosome and immune cell dynamics in cancer
Bennion, A., Lysaght, J., & Lynam‐Lennon, N. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70628 · Cited by 2
Reprogramming the tumor immune microenvironment via antibody-drug conjugates
Xu, T., Gu, Y., & Guan, X. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642215 · Cited by 2
TIM3-mediated differentiation of IL-10-producing CD25+ B cells by expanded regulatory T cells
Alhabbab, R. Y., Mastronicola, D., Lombardi, G., & Scottà, C. (2025) · Journal of Molecular Medicine · doi:10.1007/s00109-025-02606-0 · Cited by 1
Wang, Z., Ma, L., Cao, J., Lin, S., Ma, R., Wang, J., Lv, H., Zhang, Z., & Jiang, T. (2026) · Scientific Reports · doi:10.1038/s41598-025-34933-0
Chwiałkowska, K., Niemira, M., Zeller, A., Ostrowska, A., Michalska‐Falkowska, A., Reszeć-Giełażyn, J., Kozłowski, M., Mróz, R. M., Naumnik, W., Sierko, E., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07957-x
Characterization of regulatory T cells populations in breast cancers
Fattori, S. (2023) · theses.fr (ABES) · doi:10.70675/1c177425zb8daz422fza46dz677464719c36
Metadata
- Authors
- Lam, J. H., Hong, M., Koo, S.-L., Chua, C. W. L., Lim, K. L., Wee, F., Wan, W. K., Leow, W. Q., Yeo, J. G., Tan, I. B. H., Yeong, J., Lim, T. K. H., & Lim, T. S.
- Affiliations
- National Cancer Centre Singapore (SG)
- Singapore General Hospital (SG)
- SingHealth Duke-NUS Academic Medical Centre (SG)
- Agency for Science, Technology and Research (SG)
- SingHealth (SG)
- Corresponding author
- Yeong, Joe
- Lim, Tony Kiat Hon
- Lim, Tong Seng
- ORCID
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2021-02-02
- Volume
- 70
- Issue
- 8
- Pages
- 2353-2365
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC8289785
- OpenAlex
- W3129005829
- Cited by
- 31
- References
- 68
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 8 · 2023: 6 · 2022: 6
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Singapore General Hospital
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, regulatory T cells, CD30, OX40, CD45RO, tumor-infiltrating Treg cells, prognostic factors, overall survival, tumor immunosuppression, diagnostic biomarkers, tumor-infiltrating immune cells
- MeSH terms
- Cells, Cultured, Humans, Prospective Studies, Retrospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, Leukocyte Common Antigens, Ki-1 Antigen, Receptors, Cytokine, T-Lymphocytes, Regulatory, Receptors, OX40
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.